IDH2 and acute myeloid leukemia: In examining the prognostic significance of co-mutations in IDH-mutant AML, the NPM1 mutation was associated with improved OS in IDH1- or IDH2R140-mutated AML treated with intensive chemotherapy, suggesting a potential group of patients who would particularly benefit from the addition of targeted therapy [36].